Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine

Annelies Wilder-Smith, Joachim Hombach, Neil Ferguson, Michael Selgelid, Kate O'Brien, Kirsten Vannice, Alan Barrett, Elizabeth Ferdinand, Stefan Flasche, Maria Guzman, Hillegonde Maria Novaes, Lee Ching Ng, Peter G. Smith, Piyanit Tharmaphornpilas, In Kyu Yoon, Alejandro Cravioto, Jeremy Farrar, Terry M. Nolan

Research output: Contribution to journalReview article

43 Scopus citations

Abstract

The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.

Original languageEnglish (US)
Pages (from-to)e31-e38
JournalThe Lancet Infectious Diseases
Volume19
Issue number1
DOIs
StatePublished - Jan 2019

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine'. Together they form a unique fingerprint.

  • Cite this

    Wilder-Smith, A., Hombach, J., Ferguson, N., Selgelid, M., O'Brien, K., Vannice, K., Barrett, A., Ferdinand, E., Flasche, S., Guzman, M., Novaes, H. M., Ng, L. C., Smith, P. G., Tharmaphornpilas, P., Yoon, I. K., Cravioto, A., Farrar, J., & Nolan, T. M. (2019). Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. The Lancet Infectious Diseases, 19(1), e31-e38. https://doi.org/10.1016/S1473-3099(18)30494-8